The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives (Q34098002)

31 July 2017

title

The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives (English)

1 reference

31 July 2017

9

1 reference

31 July 2017

Khac-Minh Thai

1

0 references

Anna Weinzinger

object named as

Anna Weinzinger

4

0 references

Steffen Hering

8

object named as

Steffen Hering

1 reference

31 July 2017

5

Andrea Schiesaro

1 reference

31 July 2017

Andreas Windisch

2

1 reference

31 July 2017

Daniela Stork

3

1 reference

31 July 2017

Robert H Guy

6

1 reference

31 July 2017

Eugen N Timin

7

1 reference

31 July 2017

publication date

1 March 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

5

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

436-442

1 reference

The impact of drug-induced QT interval prolongation on drug discovery and development

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

hERG potassium channels and cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Predictive models for HERG channel blockers: ligand-based and structure-based approaches.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Ligand structural aspects of hERG channel blockade

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Predictive in silico modeling for hERG channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Insights for Human Ether-a-Go-Go-Related Gene Potassium Channel Inhibition Using Recursive Partitioning and Kohonen and Sammon Mapping Techniques

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Medicinal chemistry of hERG optimizations: Highlights and hang-ups

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Understanding the Structure−Activity Relationship of the Human Ether-a-go-go-Related Gene Cardiac K+ Channel. A Model for Bad Behavior

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

A structural basis for drug-induced long QT syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Molecular determinants of HERG channel block.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

State dependent dissociation of HERG channel inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

hERG potassium channels and the structural basis of drug-induced arrhythmias

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Synthesis, Pharmacologic Activity, and Structure-Activity Relationships of a Series of Propafenone-Related Modulators of Multidrug Resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Ein Verfahren zur Synthese der Enantiomere von Propafenon

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Molecular determinants of hERG channel block by terfenadine and cisapride

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Propafenone and Its Metabolites Preferentially Inhibit IKrin Rabbit Ventricular Myocytes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

A novel hypothesis for the binding mode of HERG channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

A two-state homology model of the hERG K+ channel: application to ligand binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

A novel structure-based virtual screening model for the hERG channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Drug block of the hERG potassium channel: insight from modeling.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

A binary QSAR model for classification of hERG potassium channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Classification models for HERG inhibitors by counter-propagation neural networks

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Automated fast perfusion of Xenopus oocytes for drug screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900374

7 January 2021

Identifiers

DOI

10.1002/CMDC.200900374

1 reference

31 July 2017

1 reference